Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007196
Chunk: 124

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 124
---
ary Shares at $4,640.00 per Depositary Share, (2) 12,931,20 Ordinary Shares represented by 1,293 Depositary Shares, issuable upon the exercise of Series A Warrants issued in the February Private Placement at an exercise price of $5,360.00 per warrant, (3) 19,396,400 Ordinary Shares represented by 1,939 Depositary Shares, issuable upon the exercise of Series B Warrants issued in the February Private Placement at an exercise price of $5,360.00 per warrant, and (4) 62,184,525 Ordinary Shares represented by 6,218 Depositary Shares, issuable upon the exercise of pre-funded warrants issued in the February Private Placement at an exercise price of $0.80 per warrant, for aggregate gross proceeds of approximately $6.0 million. We also issued unregistered placement agent warrants to purchase a total of 536,800 Ordinary Shares represented by 52 Depositary Shares to Ladenburg Thalmann & Co. Inc. at an exercise price of $10,000.00 per warrant for one warrant and an exercise price of $5,800.00 per warrant for 51 warrants, and Series A Warrants to purchase 625,000 Ordinary Shares represented by 62 Depositary Shares at an exercise price of $5,360.00 per warrant to an investor pursuant to a waiver.

On May 26, 2023, we completed the closing of the May 2023 Registered Direct Offering
with institutional investors of (1) 166,017,700 Ordinary Shares represented by 16,601 Depositary Shares, issuable upon the exercise of
the Series C Warrants, at an exercise price of $400.00 per warrant, (2) 110,675,600 Ordinary Shares represented by 11,059 Depositary Shares
issuable upon the exercise of the Series D Warrants at an exercise price of $400.00 per warrant and, (3) 4,426,800 Ordinary Shares represented
by 442 Depositary Shares issuable upon the exercise of the May 2023 Placement Agent Warrants at an exercise price of $375.00 per warrant.

On June 20, 2023 we issued the Series C Warrants, Series D Warrants and placement
agent warrants to the investors and the placement agent after receiving required shareholder approval of the allotment of, and disapplication
of pre-emption rights with respect to the Ordinary Shares to